AFAN Brings New Era in African Neurology

It was a momentous day in the history of African neurology. For more than 40 years, the continental neuroscience organization was an amalgamation of neurologists and neurosurgeons. The Pan African Association of Neurological Sciences (PAANS) served its purpose, and it’s time now for the establishment of an organization dedicated to neurology. Neurosurgeons already have established the Continental Association of African Neurosurgical Societies and held an inaugural meeting in Algiers.

The World Federation of Neurology (WFN) fully supported the views of neurologists across Africa to establish this association. This followed many years of discussions and consideration, since the establishment of the Task Force for Africa in 2006 during the presidency of Johan Aarli and the subsequent stakeholders’ meeting in Stellenbosch, South Africa, in 2008.

The WFN designated a third of its profits from the Marrakesh World Congress to the Africa initiative. Part of this fund was released to gather delegates from as many African neurological societies as possible to hold an inaugural extraordinary meeting in Dakar, Senegal, in August. This was arranged by Prof. Gallo Diop, WFN trustee and chair of the WFN Africa initiative, and Prof. Riadh Gouider, WFN trustee and president of PAANS.

I had the honor of attending and participating in the proceedings. Representatives from 27 African societies were present: Benin, Burkina Faso, Cameroon, Congo Brazzaville, Congo DRC, Egypt, Ethiopia, Gabon, Ghana, Guinea, Ivory Coast, Kenya, Madagascar, Mali, Mauritania, Morocco, Niger, Nigeria, Rwanda, Senegal, South Africa, Sudan, Tanzania, Togo, Tunisia, Uganda and Zambia.

The bylaws and constitution, which were drafted by Prof. Mostafa Elaloui, Morocco, were circulated in advance. After careful review, the draft unanimously was approved.

The following day and according to the bylaws, elections were held for the board of directors. Prof. Michel Dumas, Limoges France, and I supervised the proceedings. It is of note that Prof. Dumas is among the PAANS founders, and he was present to witness the founding of the African Academy of Neurology (AFAN).

The AFAN elected board of directors are:

From the Editor-in Chief
Implementation science arrives with a new dimension for advocacy.

President’s Column
International specialists and interest groups will gather in Santiago, Chile, Oct. 31-Nov. 5 for World Congress 2015.

Book Review
Murray Grossman, MD, reviews Imaging in Neurodegenerative Disorders.

Candidates for the WFN Election
Review the candidates biographical details and statements of their goals and objectives.

Dementia: A New Perspective

As dementia rises in prevalence, new approaches must be adopted in the treatment of the condition and efforts to prevent it.

Dementia means the loss of brain capacity severe enough to result in the loss of self-sufficiency. The incidence of dementia, which is rising globally, is largely driven by the aging population. Although dementia increases with age, it is not inevitable with age. Dementia represents the end stage of several processes, for which some are treatable and preventable.

Brain blood vessels (vascular) and Alzheimer’s disease represent the two most common pathologies leading to dementia. The changes of Alzheimer’s disease are characterized by the deposition of amyloid protein plaques and of tau protein aggregation forming tangles in neurons. The changes that lead to Alzheimer’s disease
Implementation Science Arrives: A New Dimension for Advocacy

The neuropathic community should congratulate itself for achieving public recognition for our field by organizing public programs. This advocacy method began with the U.S. declaration of the Decade of the Brain in the 1990s. Many other countries followed with their declarations of a year or a decade for the same purpose. In 2013, the World Federation of Neurology designated July 22, the date of its founding in 1977, as World Brain Day. Neuropathic societies in several countries organized celebrations on that date in 2014, as reported in past issues of World Neurology. The purposes for these celebrations include increasing public awareness of neuromuscular disorders and persuading governments to increase the resources needed to make care available, improve care and carry out essential research. The huge question is how to move from advocacy to improving prevention and effective clinical care in all countries. As described in the June 2014 issue of World Neurology, the Fogarty International Center at the National Institutes of Health (U.S.) is trying to help with this by developing a program to promote implementation science.

Donald H. Silberberg

WFN Accredits EMG Initiative for Young African Neurologists

The exploration of neuromuscular training, especially through the use of electromyography (EMG) in confirming a diagnosis and in classifying neuropathies, is essential to the neurologic training course. Thus, the World Federation of Neurology (WFN) took the initiative to open a training center in EMG at the Hospital of Specialties, Rabat, Morocco, to educate young neurologists training in Africa. This initiative has been widely appreciated by neurologists in sub-Saharan Africa. I had the privilege of being the first African neurologist to benefit from this training. In this report, I will share my experiences as an intern, including the different activities I led.

My 10-month training period, under the supervision of Prof. Mustapa El Alaoui Fats, ran from September 2014 to June 2015. I worked in the neurophysiology department of the Hospital of Specialties in Rabat, a public university hospital accredited by the WFN to train African neurologists since 2013. The department, headed by Prof. Reda Ouazzani, is the only accredited center in Morocco for training young neurologists. The training was a good opportunity to attend several neurology meetings, which gave instructors from all of the neurophysiology departments much-related experience and discussed all of the experiences as an intern, including the different activities I led.

In my 10-month training period, under the supervision of Prof. Mustapa El Alaoui Fats, ran from September 2014 to June 2015. I worked in the neurophysiology department of the Hospital of Specialties in Rabat, a public university hospital accredited by the WFN to train African neurologists since 2013. The department, headed by Prof. Reda Ouazzani, is the only accredited center in Morocco for training young neurologists. The training was a good opportunity to attend several neurology meetings, which gave instructors from all of the neurophysiology departments much-related experience and discussed all of the experiences as an intern, including the different activities I led.

In my 10-month training period, under the supervision of Prof. Mustapa El Alaoui Fats, ran from September 2014 to June 2015. I worked in the neurophysiology department of the Hospital of Specialties in Rabat, a public university hospital accredited by the WFN to train African neurologists since 2013. The department, headed by Prof. Reda Ouazzani, is the only accredited center in Morocco for training young neurologists. The training was a good opportunity to attend several neurology meetings, which gave instructors from all of the neurophysiology departments much-related experience and discussed all of the experiences as an intern, including the different activities I led.

In my 10-month training period, under the supervision of Prof. Mustapa El Alaoui Fats, ran from September 2014 to June 2015. I worked in the neurophysiology department of the Hospital of Specialties in Rabat, a public university hospital accredited by the WFN to train African neurologists since 2013. The department, headed by Prof. Reda Ouazzani, is the only accredited center in Morocco for training young neurologists. The training was a good opportunity to attend several neurology meetings, which gave instructors from all of the neurophysiology departments much-related experience and discussed all of the experiences as an intern, including the different activities I led.
WCN 2015: A Chance of a Lifetime

The World Federation of Neurology (WFN) holds its showcase biennial World Congress of Neurology (WCN), with Santiago, Chile, hosting Oct. 31-Nov. 5. This is the only international congress where all neurology specialties and interest groups have their chance to interact and show their progress to an international audience. The Scientific Program Committee tries to contact all interested groups to ask them to convene sessions with their proposed topics and speakers.

The choices for the number of sessions and topics are most difficult to get absolutely spot-on, and there always will be some topics or groups needing more time or attention. The Organizing Committee tries hard to have wide and varied representations. This has to be balanced against the paramount goal of bringing the most up to date science to the audience.

Participation of regional neurological associations, which have their own congresses, adds a different slant to the WCN. The six regions of the world are represented, and their sessions are left to them to organize. This is always interesting and adds element of specific regional flavor to observe and share with the entire world.

Participation of sister brain alliance organizations represented by their symposia puts another dimension to the WCN. It is most important to see that psychiatry, neurosurgery, rehabilitation, child neurology and brain scientists participate with their own symposia. This only emphasizes brain health as a single entity. Presidents of all these organizations attend and deliver their views on common topics.

It is most important for neurologists to closely interact with allied specialists in combating all aspects of diseases of the nervous system. Neurologists, psychiatrists and neurosurgeons are moving closer in understanding brain physiology, and as an example deal with issues such as deep brain stimulation in various conditions, such as movement disorders, epilepsy, depression, anxiety and obsessive compulsive disorder. On the other hand, the field of the dementia further cements the close relationship between neuroscientists, neurologists and psychiatrists. The use of fMRI has an understanding of basic brain dysfunction has been revolutionized. The WCN program brings all this to the fore, and the days of living in silos are long gone.

The World Health Organization (WHO) and interest in non-communicable diseases is the way to move ahead in promoting neurological education and care. The WCN offers a symposium jointly with the WHO, as it has done previously, to make sure the voice of neurology is heard at the highest levels among decision-makers who control the provision of health care across the world. It is absolutely crucial that neurologists keep politicians and economists fully engaged and aware of the devastating consequences of brain diseases and the impact upon society.

The WCN is a major teaching opportunity for many, and the teaching courses are intermingled with scientific presentations to attract the maximum number of attendees. It is always a major task for the organizers to hold themed teaching courses and scientific sessions on the same days to keep the linear structure of a congress.

The WCN moves continents for good reasons. The WFN provides education and exposure to neurologists from all over the world, and hence the emphasis may be different in different locations. This is encouraged in order to maintain the individuality and different flavor of each congress in order to avoid carbon copy congresses.

For several congresses now, the WFN has made a point on inviting a Noble laureate to deliver the keynote presentation. The XXII congress is no exception. Prof. Thomas C. Sudhof, Noble laureate in physiology or medicine 2013, will deliver “Neurexins and Neurexins: Toward a Molecular Logic of Neuronal Circuits.” Nov. 2.

There is now huge emphasis on the place of neurology in the fight against non-communicable diseases. The WHO and the United Nations have taken a major step, and all their agencies are working hard to promote this goal. The WFN has a major role to play as an official WHO partner, and the WCN is a prime showcase venue for the activity. The WHO leadership is well represented, and input will help to move brain health ahead. WHO Assistant Director General Oleg Chestnov will deliver a plenary lecture on the current status of non-communicable diseases and the role neurology is expected to play in the process.

Every neurologist knows well that our specialty has changed even over the short and medium term. We are now at the coalface with respect to acute care provision with stroke management and work in intensive care units. This is well represented in the congress, and there is so much to learn.

Is it correct to say that the days of general neurologists are numbered, and, if so, how are we ready for it? This may be true in the developed parts of the world, where, for instance, a muscle specialist will not be able to confidently run an epilepsy clinic. It is also true that genetics have opened a whole new world in diagnosis and soon treatment. We now live in a world where in April 2013, the British public represented by their parliament voted to approve mitochondrial gene donation. And the world is on the cusp of huge gene therapy changes, which will come with the use of clustered regularly interspaced short palindromic repeats, CRISPR-Cas9 technology for short. Perhaps within a generation, neurologists and their patients will be able to see a huge change in practice.

The ability to understand and deliver care at a high level is not easy and at times impossible. One of the roles of the congress is to bring all the expertise of the super specialist to generalists so they may interact, and this can only be done in a general multifaceted setting.

Moving to the business of international neurology, the WCN is the only venue for all world neurological societies to come together and interact to organize international affairs in various WFN committees. The main purpose of the WFN is to promote quality neurology worldwide, and this can only be achieved with the full cooperation of all neurological societies and their regional organizations.

The highest authority of the federation is the council of delegates (COD). Each member society is represented, and on Nov. 1 the council will meet to go through WFN affairs. The elected trustees and committee chairs will present last year’s activities and the status of finances. There will be elections for a newly created post of WFN treasurer. The last COD following recommendations of the trustees voted to split the post of secretary-treasurer general into two; hence this post was created. There also will be an election for one trustee post, which was vacated when the current secretary-treasurer general assumed his role at the beginning of 2015.

The WFN follows a rotation system in holding its world congresses. This system has worked so far to move the congress to four regions. Europe, Asia-Pacific, Latin America, Pan-Arab/Africa, and the Americas. Following Kyoto in 2017, the turn is on the combined Africa/Pan-Arab regions. Two candidate cities—Cape Town and Dubai—were visited and inspected by the WFN Congress Committee. The delegates will have a chance to hear and see presentations and reports, and then have a vote to choose the venue for 2019.

On behalf of the WFN, the trustees welcome you to Santiago to enjoy a most spectacular venue in a most exciting and beautiful country. Our Chilean colleagues with the WFN Scientific Program Committee have laid out a phenomenal program, and I have to add that visiting Chile and it diverse north and south is a pleasure not to be missed. For many, it’s a chance of a lifetime.
Stroke is a devastating and debilitating disease. It is the second leading cause of death in the world, comprising approximately 10 percent of all deaths and killing 6.5 million people each year, with 44 million disability-adjusted life years (DALYs) lost. In 2010 alone, there were 16.9 million strokes worldwide, of which 70 percent occurred in low- and middle-income countries; this trend is expected to increase over the next 20 years.

Presently, low- and middle-income countries account for more than 85 percent of the global stroke mortality. Stroke mortality rates are especially high in Africa and Asia, where the burden of preventing and treating communicable diseases is shifting resources away from cardiovascular disease and stroke. However, the burden from chronic and non-communicable diseases is likely to exceed the burden from communicable diseases in low- and middle-income countries in the near future. A global focus on reducing mortality and morbidity from cardiovascular disease and stroke is more urgent than ever. Major problems shared by many countries are a lack of infrastructure, inadequate systems of care, effective programs to address cardiovascular risk factors, financial difficulty and shortage of trained health care workers. Advocacy efforts, partnerships between countries, efficient and cost-effective targeted interventions and allocated funding and resources are necessary to tackle the worldwide stroke burden.

Stroke began to be tracked globally via surveillance systems in 1968 with the World Health Assembly, after which data including incidence, mortality and case-fatality was tracked. In more recent years, a more sophisticated stepwise approach to stroke surveillance has been recommended by the World Health Organization to include not only individuals with non-fatal events in the community, but also those admitted to the hospital. Stroke risk factors are also tracked using a stepwise surveillance approach, including demographic and self-reported data, physical examination and objective laboratory results.

These measures have helped to show the great disparity between low- and middle-income countries and high-income countries, with national per capita income being the highest predictor of stroke burden, exclusive of cardiovascular risk factors.

Overall, between the countries with the highest stroke mortality and the lowest stroke mortality, a tenfold difference in age-adjusted mortality rates and DALYs lost was observed. Globally, the highest at-risk countries are in Eastern Europe (with Russia having the highest stroke mortality rate), Asia and Africa, along with some in the South Pacific and the Caribbean. The economic impact of stroke has also been severe. For example, in 2005 it was estimated that the losses to gross domestic product due to vascular diseases was nearly $1 billion in China and India. This economic disparity is expected to increase in the near future in low- and middle-income countries.

Health systems of care for stroke require financing, staffing and structure in order to produce results. For example, the administration of intravenous alteplase (IV tPA) has been seen to significantly improve outcomes after acute ischemic stroke. However, giving IV tPA appropriately to eligible patients requires infrastructure and organization. Several countries have successfully developed systems to administer IV tPA (e.g., Brazil, Argentina, China and India), but there are still many barriers in low-income countries where medical services may be scarce and not easily accessible due to geography or human resources, and IV tPA may be prohibitively expensive.

In addition, funding is not proportional to economic and patient burden. For example, in 2011, funding for three of the major infectious diseases (HIV/AIDS, tuberculosis and malaria) was 35 times greater than funding for all non-communicable conditions combined. Therefore, besides the need for much greater funding in the realm of stroke and cardiovascular diseases, it has been suggested that community interventions and a focus on primary care might be the most cost-effective and efficient approach to stroke on a global level.

Although stroke burden is significant regardless of cardiovascular risk factor burden, the overall risk factor burden is increasing in low- and middle-income countries. For instance, hypertension is held accountable for approximately 54 percent of global stroke burden, this could be especially important as a target for intervention in countries such as China, where rates of hypertension are increasing. As many of the population in low- and middle-income countries with stroke are working age (41-65) adults, more smoking has been seen in working-age adults than in other age groups.

The obesity epidemic continues to rise (with an estimated 10 percent of children globally considered overweight). The three-year INTERSTROKE study, based in 84 centers in 22 countries, confirmed that 88 percent of strokes were attributable to 10 risk factors: hypertension, smoking, waist-to-hip ratio, diet risk score, physical activity, diabetes mellitus, alcohol intake, psychosocial factors (including depression and stress), cardiac causes and the ratio of apolipoprotein B to apolipoprotein A1. The study, published in 2011, noted that targeting these risk factors on a primary care level, and focusing on healthy lifestyles, could substantially improve the global stroke burden.

Other targets for low-cost, high-efficacy interventions could include educational campaign programs, such as the Go Red for Women Campaign and World Heart Day, which have been effective in spreading education and increasing disease awareness. In addition, cost-effective interventions such as the polypill, which incorporates three medications into a single pill, could help reduce costs and improve compliance with medications.

It also may be beneficial to incorporate new and innovative, yet still cost-effective, techniques to address the global burden of stroke. Some innovative approaches to address primary stroke prevention, namely by using smartphone technologies, have been suggested and are being tested. Researchers from New Zealand have developed the Stroke Riskometer app, which assesses responses to a short questionnaire and determines the five- and 10-year risk for stroke using a validated algorithm similar to the Framingham risk score. It also incorporates education, comparison with similar individuals and an opportunity to share risk assessment results with others. An update of this app allows for participation in an international epidemiological research study (the Reducing the International Burden of Stroke: Using Mobile Technology, or RIBURST study), which involves more than 160 countries.

Besides the interventions on a patient and community level, countries with high rates of stroke mortality must set priorities that are attainable and commensurate to resources. Better definition of stroke traits and determinants in low- and middle-income countries are needed to develop culturally specific stroke prevention strategies. International agencies must work together to develop more novel strategies to attack the stroke epidemic. The UN General Assembly already has attempted to do this by setting a goal of reducing mortality from non-communicable diseases by 25 percent by the year 2025. Collaboration, vision and innovation are needed to reduce the global stroke burden and the stroke disparities that exist between countries.

References


Sarah Song, MD, MPH, is an assistant professor in the Section of Cerebrovascular Disease, department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois.
Book Review: Imaging in Neurodegenerative Disorders

OXFORD UNIVERSITY PRESS, 2015

BY MURRAY GROSSMAN, MD

Neuroimaging is an important adjunct to clinical neurology. We cannot easily examine the brain directly. The neurologic exam is designed to allow us to make reasonable inferences about abnormalities of neurologic functioning, and neuroimaging helps us visualize the brain. This significantly enhances our ability as clinicians to diagnose the cause of a neurologic abnormality and monitor response to an intervention. This is particularly true in neurodegenerative diseases, where the neurologic exam has been immensely assisted by neuroimaging. Indeed, with advances in neuroscience knowledge, novel imaging techniques have been developed to provide additional insights into neurologic functioning in health and disease.

Prof. Luca Saba has edited a comprehensive textbook Imaging in Neurodegenerative Disorders (Oxford University Press, 2015, 562 pages including an index). As the title indicates, this volume focuses on neurodegenerative diseases. While neurodegeneration has been an elusive domain of neurology, recent advances in imaging have contributed importantly to advancing clinical and scientific knowledge in this area.

The book consists of 10 sections. The introduction focuses on specific background knowledge areas, such as epidemiology, health economic considerations and molecular biology. A lengthy chapter is devoted to symptoms associated with neurodegenerative diseases, and readers might have found it easier to have portions of this chapter included in sections devoted to imaging of patients with the corresponding conditions.

Imaging techniques are presented in section two, which chapters devoted to computed tomography, magnetic resonance imaging, nuclear medicine and positron emission tomography. Although recent advances in techniques related to positron emission tomography are discussed, it is unfortunate that there is not an equivalent chapter on advances related to magnetic resonance imaging.

The heart of the text is in the subsequent seven sections. Each is devoted to a specific domain within neurodegeneration. Two large sections are devoted to disorders of cognition and movement disorders. The Cognition Section includes chapters on Alzheimer’s disease and an authoritative chapter on frontotemporal dementia by Jennifer Whitwell.

The Movement Section includes chapters considering Parkinson’s and Huntington’s diseases. This area of neurology is undergoing an important revolution. As treatments emerge for the underlying histopathologic abnormalities, classification based on phenotype gradually is giving way to classification based on targets of treatment, namely, pathology.

Phenotype-based classification has resulted in the inclusion of the chapters considering dementia with Lewy bodies and corticobasal syndrome in the Cognition Section, while conditions caused by similar histopathologic abnormalities, such as progressive supranuclear palsy (a tauopathy) and multisystem atrophy (a synucleinopathy), are placed in the Movement Section.

The section on strength contains a single authoritative chapter by Martin Turner, who considers imaging in amyotrophic lateral sclerosis. A considerable portion of this chapter is devoted to extramotor brain involvement. This appropriately acknowledges that up to half of patients with amyotrophic lateral sclerosis have cognitive deficits, and suggests that the title of the section might be adjusted.

Additional sections include chapters discussing coordination, demyelinating disorders, trauma and the peripheral nervous system. The final section is devoted to neuroimaging after therapy. This is a crucial consideration as therapies emerge for neurodegenerative diseases. It might have been useful here to consider quantitative measurement in neuroimaging since many of these techniques are being used as endpoints in treatment trials.

Imaging in Neurodegenerative Disorders is a comprehensive text that has an appropriately broad scope. Chapters are devoted to all the key areas in neurodegeneration, and the chapters are comprehensive. The book is generally well illustrated, although occasional images seem to have lower resolution than is needed to illustrate a finding optimally. I recommend this text to students of neurodegeneration who are interested in a comprehensive introduction to neuroimaging.

Murray Grossman is a professor of neurology, Penn Frontotemporal Degeneration Center, at the University of Pennsylvania, Philadelphia.

Report From the Congress of the European Academy of Neurology

BY NINO GOGATISHVILI, MD

I was awarded a World Federation of Neurology travel grant, which enabled me to attend the important and interesting First Congress of the European Academy of Neurology, June 20-23, 2015, in Berlin, Germany. I am grateful for the support of World Federation of Neurology.

The well-organized congress offered an interesting scientific program. I am grateful for the support of World Federation of Neurology. The well-organized congress offered an interesting scientific program.

The well-organized congress offered an interesting scientific program. I am grateful for the support of World Federation of Neurology. The well-organized congress offered an interesting scientific program.

Preliminary Data” during the Child and Developmental Neurology session (©2015 European Journal of Neurology, 22 (Suppl. 1), 120-483). I enjoyed the great opportunity to receive remarks from my colleagues from Europe about our study.

Nino Gogatishvili, MD, is a pediatric neurologist and a PhD student at the Institute of Neurology and Neuropsychology, Tbilisi, Georgia.
Considering that book printing was invented in the early 15th century (Johannes Gutenberg, Mainz, Germany) and the copying of texts before that period had to be done by hand, one wonders whether writer’s cramp has been described in the middle ages.

As far as I now, it has not been referred to before the description by the Italian physician Bernardino Ramazzini (1633-1714) who, in 1713, published a book on occupational diseases and since then has been considered the father of occupational medicine. His book De Morbis Artificum Diatriba (Diseases of Workers) indeed contains a large number of occupations with associated disorders. In the chapter “Diseases of Secretaries, Clerks, Writers and Copyists,” Ramazzini started to refer to the ancients, who had more copyists and writers than in his days, and to the Roman writer and naturalist Pliny, who, on his journeys, was usually accompanied by a writer with a book and tablets.

In Ramazzini’s own environment, secretaries and clerks of princes, magistrates and merchants were paid to keep the books, and registers and were “subject to several diseases that depend either to the sitting position that they are obliged to conserve for long periods, or from the continuous movement of the same hand, or finally from the mental effort necessary not to make errors in their calculations.”

He continued to describe the necessity to hold the quill continuously and move it for writing, and that it fatigues the hand and even the whole arm, due to the continuous contraction of the muscles. Ramazzini was acquainted with a writer who had been writing his entire life, by which he had gathered some fortune. He experienced at first a considerable lassitude in his whole arm that resisted against all kinds of remedies, and that ended in a complete paralysis of that arm. He taught himself to write with his left hand, but, after some time, the arm became afflicted with the same disease.

Ramazzini added that the mental efforts, to which clerks are subject, may result in migraines, colds and swelling of the eyes. To prevent these diseases, the author advised to do exercises in the evening and during holy days. Interestingly, he also wrote that “the use of tobacco may diminish their headaches,” and for the paralysis of the hands, they should wash them with aromatic wine or liquors.

The well-known Scottish surgeon Charles Bell — of Bell’s palsy — may have presented an early observation in the 1833 edition of his Nervous System of the Human Body, where, under the title “Partial Paralysis of the Muscles of the Extremities,” he wrote that it is an obscure object … an affection of the muscles which are naturally combined in action.” Bell found the action necessary for writing gone, or the motions so irregular, as to make the letters be written in zigzag, while the power of strongly moving the arm, or fending, remained.

In German language, the disease was referred to as mogigraphie and schreibekrampf. Georg Hirsch, physician at Königsberg, was among the early German authors on the subject. The most particular form of partial abnormal muscle movement is the writer’s cramp, for which I propose as technical name mogigraphie, in analogy to Mogilalia.

The extraordinary disease could not be localized in the muscles, but was believed to arise from a general nerve irritation that is only present in muscles fatigued after much writing. The thumb and secondly the index finger are most often involved, with the text noting the illness is described easily as shaking, or as stiffness, mostly as a hasty flexion movement. He also referred to Moritz Reuter, who told about a 30-year-old famous composer “to whom, since 10 years, every time when playing the piano, the right middle finger fails by upcoming spasm,” possibly referring to Robert Schumann. The origin of writer’s cramp was thought to be in the spinal cord (hence the book’s name, spinal neurosis), and a section of a tendon was also referred to Moritz Reuter, who told about a 30-year-old famous composer “to whom, since 10 years, every time when playing the piano, the right middle finger fails by upcoming spasm,” possibly referring to Robert Schumann. The origin of writer’s cramp was thought to be in the spinal cord (hence the book’s name, spinal neurosis), and a section of a tendon was

Charles Bell’s The Nervous System of the Human Body (1833 American edition)
Duchenne's case 213, Matthieu Guérin


**WRITER'S CRAMP**

continued from page 6

when he wrote for a certain period of time. He suffered from pain and fatigue in his thumb and index finger, which forced him to hold the quill tightly. The fatigue would spread through his entire arm. He did not experience any symptoms when using his hand for other tasks. He was treated by six vesicatories and by douches using his hand for other tasks. He was consulted. He treated the patient with aromatic vapors without any relief. Two years later he was not able to hold his thumb and index finger, which forced him to give up his job as a cashier. In 1859, he presented at the clinic of Auguste Nélaton, where Duchenne was consulted. He treated the patient with electricity and an apparatus to keep his hand to the other side. “Aujourd’hui, après la quinzième séance, le malade peut être considéré comme guéri,” which means he was cured from the cervical dystonia following the 15th treatment session, but the writer’s cramp did not disappear.

Introducing other cases of crampes des écrivains, he wrote that the affliction was known in Germany with the name schreibekrampf. He had noticed that the muscles involved could vary. In a stockbroker, he observed flexion of the index finger as soon as he had written a few words. In an office worker at the war ministry, the first two fingers took an opposing position upon writing. Duchenne also saw supination of the hand. The treatment of what he called spams fonctionnel was usually disappointing. He applied local faradisation during 12 years in 30 or 35 cases, but only saw two successful cases.

Duchenne also observed a case of primary writer’s tremor, noting that “Mr. X. …, lawyer, 26 years old … writing about three hours a day, was affected, in the course of the month of January 1860, by tremors of the right hand, with trouble making letters. … Even the idea of writing seems to lead to tremor, that also increases when someone is looking at it. … The tremor is provoked by no other use than that of handwriting.”

Obviously, writer’s cramp has been described in many countries and most probably already existed prior to Ramazzini’s description. Perhaps other than (medical) sources should be consulted to find them.

1. Patissier Ph. Traité des Maladies des Artisans et Celles que Résultent des Diverses Professions, Ballière, 1861.

---

**Editor’s Update and Selected Articles From the Journal of the Neurological Sciences**

**BY JOHN D. ENGLAND, MD**

**EDITOR-IN-CHIEF**

The editorial staff of the Journal of the Neurological Sciences (JNS) and Elsevier have been working closely with the organizers of the upcoming XXII World Congress of Neurology (WCN) to provide easy access to the 1,461 abstracts being presented there. All of the abstracts will be published in JNS and will be available online as open access just before the congress begins.

Additionally, there will be a congress app, which will include a link to the journal to ensure that attendees can view all the abstracts. The congress venue will have Wi-Fi in the public areas. Attendees without smartphones or mobile devices will be able to access the abstracts at Internet and abstract viewing stations. I believe that these processes will enhance everyone’s educational and social experiences at the congress. I look forward to meeting with many of you at the WCN 2015 in Santiago, Chile.

In our ongoing attempt to enhance accessibility of JNS articles to members of the World Federation of Neurology, we have selected two more free-access articles, which are profiled in this issue of World Neurology.

1. Wildea Lice de Carvalho Jennings Pereira, et al., provides a comprehensive review of neuromyelitis optica (NMO). Ever since the discovery of the specific antibody against aquaporin-4 (anti-AQP4), which is associated with NMO, there has been great interest in this disease. Most of the major neurology and neuroscience journals, including JNS, publish several original articles each year describing new aspects of NMO. This article is very useful and timely, since it summarizes the current knowledge of the epidemiological, clinical and immunological aspects of the disease. It also describes the currently recommended treatment strategies for NMO. J. Neurol. Sci. 355 (2015): 7-17.

2. Joerg-Patrick Stubgen provides a summary of the types of peripheral neuropathies that are associated with lymphoma. Clinically-evident “dysimmune” neuropathies occur in approximately 5 percent of patients with lymphoma; however, electrophysiologically-evident neuropathies have been reported in as many as 35 percent of patients with various types of lymphoma. And, these prevalence assessments do not include the frequent treatment associated (largely chemotherapy-induced) peripheral neuropathies. The spectrum of peripheral neuropathies associated with lymphomas is wide, and the etiology is complex and poorly understood. As emphasized in the article, accurate clinical diagnosis of the type of neuropathy and proper categorization of lymphoma are both important to ensure selection of the most appropriate and effective treatment strategies. J. Neurol. Sci. 355 (2015): 25-36. •

Candidate Statement for Elected WFN Trustee

MORRIS FREEDMAN, MD

I have had the privilege to serve as Canadian delegate to the World Federation of Neurology (WFN) since 2007, as a member of the WFN Education Committee since 2010 and as co-chair of the eLearning Task Force of the Education Committee, alongside Prof. Riadh Gouider from Tunisia. I am also honored that the Canadian Neurological Society has nominated me for the important position of WFN trustee.

Background and Achievements

By way of background, I am chair of the International Development Committee of the Canadian Neurological Sciences Federation, and I have served as president of the Canadian Neurological Society, Canadian Congress of Neurological Sciences (now Canadian Neurological Sciences Federation) and Federation of National Specialty Societies of Canada.

At the hospital level, I am head of neurology, executive medical director of the Centre for Memory and Neurotherapeutics, and director of the Sam and Ida Ross Memory Clinic at Baycrest Health Sciences. At the university level, I am a professor in the Division of Neurology, department of medicine, and director of the Behavioral Neurology Section, Division of Neurology, University of Toronto.

My clinical focus is behavioural neurology. I am also a scientist at the Rotman Research Institute of Baycrest Centre. My research is aimed at both improving our understanding of the mechanisms underlying cognitive impairment due to frontotemporal dementia and Alzheimer’s disease and development of cognitive test procedures. For example, my colleagues and I have contributed to the use of clock drawing as a bedside cognitive assessment tool.

I have taken an active international leadership role in education. Since 2005, I have focused on eLearning using video-conferencing as an electronic medium to bring together health care professionals from across the globe within a virtual classroom. This has been done within the context of international videoconference rounds in behavioral neurology. The goal is to develop greater international communication and links in behavioral neurology, and to transfer knowledge at the basic science and clinical levels internationally through joint educational programs. American, Canadian, Cuban, Israeli, Jordanian, Russian, Saudi Arabian, Spanish, and Swiss (World Health Organization) hospitals have participated. The audiences are multi-disciplinary and include neurologists, psychiatrists, geriatricians, family physicians, nurses, social workers, occupational therapists and psychologists, as well as trainees in these disciplines. I was awarded the prestigious Colin Wolf Award from the Faculty of Medicine, University of Toronto, for this initiative.

An important development that was modeled on the international behavioral neurology videoconference rounds was the formation of an international neurology resident initiative in 2008, i.e., the Neurology International Residents Videoconference and Exchange (NIRVE), which promotes international collaboration among neurology residents. Participating sites have included Brazil, Canada, Chile, Ethiopia, France, Jordan, Nigeria and Russian. In addition to the rounds, NIRVE has led to resident exchange visits between Russia and Canada.

More recently, I have collaborated with Prof. Riadh Gouider to create a new series of international videoconference rounds in behavioral neurology involving Africa and Canada, which was supported by a WFN grant awarded during Dr. Vladimir Hachinski’s term as WFN president.

Goals

My goal as WFN trustee is highly focused and directly related to the mission of the WFN. This is to promote ‘global neurological education and training with the emphasis placed firmly on under-resourced parts of the world.’ I hope to achieve this goal through innovative eLearning programs, which will include a significant expansion of our network of international sites for video conference rounds that target neurologists, allied health care professionals and trainees in neurological and related disciplines. The focus will be expanded from our highly successful behavioral neurology series to include a broad spectrum of areas within neurology with the opportunity of adaptation of new technologies. The ongoing programming series will involve both developing and developed countries so that knowledge can be transferred from one to the other in both directions. I recognize the financial challenges facing under-resourced parts of the world, and the barriers that this poses for successful knowledge transfer through eLearning. However, in keeping with the mission of the WFN to promote global neurological education and training in these regions, I will apply all the resources at my disposal to help fulfill this mission with full emphasis on under-resourced regions.

I have a vision, a clear sense of direction and the focus to facilitate knowledge transfer for enhancing brain health across the world, especially where it is needed the most. Those who know me say that I am an excellent team player and organizer, qualities that are essential for success of the outlined goals. This success will require extensive collaboration and coordination involving many people with diverse needs, across many countries, to promote the WFN’s mission in global neurological education and training.
approach aimed at maximizing income, using income as available to fund projects around the world and efficient administration. Prudence requires that projected income streams be realistic and take into account uncertainties related to pharmaceutical industry support.

As treasurer of the Sydney 2005 World Congress of Neurology (which was a huge financial success and has contributed to WFN’s capacity to fund ongoing projects) and of the Australian Association of Neurologists (1997-2003) during a period of its growth, I am well aware of the challenges facing an organization such as the WFN and of the need for careful and prudent management of its finances. These positions naturally involved efforts to maximize income from industry, as well as other sources, so I am familiar with what is required to achieve success in these areas. The experience of being treasurer of WCN 2005 also highlighted the need to be acutely aware of the potential effects of fluctuations in exchange rates and other consequences of the globalization of economies.

WCN 2005 took place at a time of substantial exchange rate volatility, and the measures that had been put in place to minimize adverse impacts of this volatility contributed to the financial success of the conference.

The WFN has a strong tradition of efficient use of funds. Of course, contrasts with the situation in some other high profile international organizations and relies on the generous donation of time from the executive, as well as the hard work of administrative staff. This efficiency must continue.

If elected, I undertake to work diligently with the executive to ensure that the financial management of the WFN allows it to pursue its aims and objectives as effectively as possible. •

NEW ERA

continued from page 1

• President: Mansour Ndiaye, Senegal
• President Elect: Youmi Ogun, Nigeria
• Secretary General: Augustine Chawaraya, Ghana
• Treasurer: Lawrence Tucker, South Africa
• Five Regional Vice Presidents: Central Africa, Alfred Njamnshi, Cameroon; East Africa, Oskhe Sidi, Sudan; North Africa, Foad Abd-Allah, Egypt; South Africa: Alain Tchindzuanamvelo, Madagascar; and West Africa: Agnon Balogou, Togo

The AFAN council of delegates approved the establishment of a permanent secretariat in South Africa, with all the necessary legal implications and registration as a non-profit organization. Lawrence Tucker, AFAN treasurer, will undertake the task.

With the formation of AFAN, the sixth chair of the WFN regional organizations is now complete. I am sure that all of us wish our African colleagues all the best in their tireless work to promote and deliver neurological care in Africa.

EMG INITIATIVE

continued from page 2

epilepsy syndrome occurring in the department of neuropathology at the Hospital of Specialties from 2005 to 2015. The study is being written for possible publication.

My neuropathology training gave me a great opportunity to fill my shortcomings in this discipline. I am pleased with how Prof. El Alaoui and Prof. Ouazzani were so transparent and available to me.

My recommendations to WFN are to:
• Ensure the continuity of this initiative.
• Provide EMG continuing education support to allow us to consolidate our gains.
• Determine the young neurologists who will benefit from this training, ultimately encouraging them to train others in other countries in a spirit of solidarity.

I want to thank everyone who contributed to the success of my internship in Rabat. I particularly would like to express my sincere thanks to Prof. El Alaoui Faris for his advice and encouraging the success of my training. I sincerely thank WFN for giving me this continuing education opportunity. I thank Prof. Ouazzani for his teaching during my time in service. My thanks also go to Prof. Briouk for her willingness to initiate us into the best kept secret of EMG. I cannot forget to warmly thank warmly Professors H. Belaid, B. Kably, F. Lahoussi and L. Erriug for their availability and their teachings.

Finally, I deeply thank my family in Mali, who supported me in my studies long ago. I owe them what I am today. •
I am a professor emeritus of neurology and former head of the Department of Neurology, University of Basel, Switzerland. I have been a member of the Executive Committee of the European Neurological Society (ENS) since the foundation of the society and was president of the ENS. I was in charge of its finances and served as treasurer. I chaired the Evaluation Committee of the ENS fellowship program and was a member of the Examination Committee of the European Board of Neurology. My research interests have centered on immunoneurological aspects of neurological diseases, such as multiple sclerosis, inflammatory neuropathies and paraneoplastic syndromes. I am currently the president of the Scientific Council of the International Foundation for Research in Paraplegia in Geneva and chair the Neuromuscular Research Association Basel. I am a member of several international societies, such as the Neuromuscular Research Group of the WFN and a faculty member of F-1000. I am a past editor of the Swiss Archives of Neurology and Psychiatry, a former president of the Swiss Neurological Society and a regular reviewer of scientific journals. I am a fellow of the American Neurological Association and a fellow of the European Academy of Neurology.

Large international organizations, such as the WFN, need a strong management structure to sustain the challenging demands in a rapid moving world. This has led to the decision to separate the post of secretary-treasurer general into two, one of secretary general and the other of treasurer. In high insight, this is a natural evolution toward more transparency, and most scientific societies today follow this model. The newly created function of treasurer is an important position of trust and responsibility situated between the president, secretary general, trustees and member societies. Over the years, the WFN has experienced increased operating expenses, in particular through its worldwide initiatives, grants and spending on member activities, which help to realize its main goals as a global scientific society. In this respect, an important role of the treasurer is to keep the WFN on a sound and sustainable financial basis, while allowing the WFN to meet its growing support needs by encouraging new projects and co-sponsorships with other institutions or scientific societies. While the WFN is by essence a global player, there are an increasing number of large international neurological societies taking regional and supranational coordinating roles. An example of this is the newly created European Neurological Society (EAN). The two existing European neurological societies, the European Neurological Society (ENS) and the European Federation of Neurological Societies (EFNS), have now joined forces to build the EAN. The newly established organization has inherited funds of the two previous ones. This puts it in an excellent position to take on new challenges, such as a recently initiated partnership program across the Mediterranean to involve associate member countries. The newly formed Pan American Federation of Neurological Societies (PANFS) is representing neurology in Latin America a region in full development, where the 22nd World Congress of Neurology (WCN) is taking place in Santiago, Chile. The 23rd WCN will be organized by the Asian Oceanian Association of Neurologists and take place in Kyoto, Japan.

The WFN should take advantage of the unique opportunity to collaborate with these international societies to advance our field. The challenge for the WFN in the coming years will be to coordinate its global involvement by interacting not only with national, but also new international scientific organizations. In order to maintain a sustainable growth, the cooperation’s projects should be well planned to avoid overlapping programs. A better integration and coordination of the WFN applied research groups would help foster quality neurology worldwide. Efforts should be made to streamline the budgeting process and assure that management accounting allows for an ongoing monitoring of income and expenditures.

Candidate Statement for WFN Treasurer

Andreas Steck, MD

Dementia continued from page 1

begin about 20 years before any symptoms appear. Many elderly individuals die with plaques and tangles without having had any trouble in life as a result. Similarly, most vascular disease is insidious. For each stroke that affects the body, five affect the mind, usually with the person being unaware of them.

While Alzheimer’s and cerebrovascular pathology occur commonly with age, mostly without symptoms, the combination doubles the chances that the dormant pathologies will result in dementia. Although cerebrovascular disease is treatable and preventable, scant attention has been paid to this component, present in 80 percent of Alzheimer’s patients.

Instead, the declared intention is to find a cure or disease-modifying drug by 2025. The idea of giving one drug to an amalgam of pathologies broadly defined as Alzheimer’s disease may prove as disappointing as the itinerary of failed trials that took place in the late 1990s and early 2000s aimed at stopping the damage that follows a stroke with a single drug. Since dementia has multiple causes, one must try multiple therapies, including addressing the one component that can be treated and prevented: the vascular one.

Dementia is not a threshold but a continuum. The process begins decades before any symptoms appear, a phase termed the “brain-at-risk stage.” The earlier the risk factors are recognized and treated, the better the chance of success. Knowledge accrues in pieces, but is understood in patterns. Specialization fosters fragmentation and fieldisms. It turns out that all major brain diseases result from different combinations of half a dozen mechanisms. By integrating this knowledge, researchers may discover that drugs developed for one purpose in one field may have application in another. If we only knew what we already know.

The Need for Multiple Therapies

The diagnosis of Alzheimer’s disease is notoriously imprecise, mainly because most patients harbor multiple pathologies. Even if a drug were 100 percent effective in blocking amyloid deposition, its effect might be obscured or overwhelmed by concomitant pathologies, for example brain vascular disease and its interactions, such as inflammation, if not treated at the same time. This calls for multiple therapies and new methodologies, such as platform trials to evaluate multiple therapies simultaneously. The lack of precision in diagnostic categories can be overcome by identifying specific contributing mechanisms leading to dementia and treating them. It is now possible to image vascular disease, amyloid and tau protein deposition and inflammation in the brain. Each of these mechanisms can be treated individually or in combination.

The evaluation of drugs can be accelerated by developing protocols in close reciprocal interactions with experimental work in a few advanced centers. These would continue with extensive protocols and thorough evaluation of patients. Once experience has been gained, a protocol could be simplified so that large numbers of patients could be enrolled. At predetermined intervals, statistically valid samples of patients following the simplified protocol would be studied by those following the extensive study protocol to make sure that they were similar. In the era of big data and electronic records, it may be possible to do more sophisticated post-marketing surveillance and gain real-world knowledge of the effectiveness of different treatments.

Unhealthy diets, physical inactivity and tobacco and alcohol addiction represent identifiable risks for stroke and dementia and other non-communicable diseases targeted by the United Nations resolution of September 2011. In order to succeed, a three-step approach is required:

1. Information
2. Motivation
3. Enablement

Good information is essential, but by itself is no more effective than New Year’s resolutions. Motivation matters but is seldom addressed. Healthy lifestyles require a healthy environment, and policymakers have a particular role in creating it. They also have a leadership role in introducing legislation to curb tobacco and alcohol use and limit the consumption of unhealthy foods. They also have a major role in ensuring that our air is breathable. Air pollution can harm the lungs, damage the heart and afflict the brain. What happens in Beijing matters at Schloss Elmau. We share the same biosphere. Policymakers can follow the lead of Finland in considering health in all policies. Public health could be enhanced considerably through the leadership of non-governmental organizations. Additionally, policymakers can get help from international brain organizations, which can provide expertise and patient support groups, and can help to mobilize the public toward healthier lifestyles and risk-factor control, which may prevent or postpone major chronic diseases, including dementia.

Conclusions

Dementia results most often from a combination of Alzheimer’s and cerebrovascular pathologies and their interaction. Cerebrovascular disease is both treatable and preventable.

The diagnosis of dementia is imprecise, but it is now possible to identify and target the different mechanisms leading to brain deterioration. This will require multiple interventions and new clinical trial methodologies.

Dealing with the challenges of dementia will require not only new resources, but also new thinking and different approaches as well.

Vladimir Hachinski, MD, is the Distinguished University Professor at Canada’s University of Western Ontario. With John W. Morris, he founded the world’s first successful acute stroke unit. With David Cockett, he discovered the role of the brain’s insula in sudden death, and, joined by Shawn Whitehead, they established a treatable link between Alzheimer’s disease and stroke. He has authored, co-authored or co-edited 17 books and more than 600 widely cited publications. He was president of the World Federation of Neurology from 2010 to 2013 and the founding and past chair of the World Brain Alliance.

Article originally published in G7 Germany: The Schloss Elmau Summit. www.g7g20.com.
Candidate Statement for WFN Elected Trustee

DANIEL TRUONG, MD

My association with the WFN gave me the opportunity and cover to safely develop educational programs for Vietnam, as Vietnam had just begun opening its doors to the West. I implemented the format of the International Neurology Forum, consisting of a short course focused on one topic lasting one to two days. This format was the product of repeated observations that physicians from developing countries did not demonstrate high retention of new techniques learned from broad, lengthy meetings. However, when trained collectively in a large group in their own countries, there was a much higher chance that their practice patterns would change. I organized this format in subsequent forums in developing countries, such as Mongolia, Indonesia, Uzbekistan and Kazakhstan.

Over the years, I also have served on the Fundraising Committee, Membership Committee, Education Committee and Editorial Boards of World Neurology and the Journal of Neurological Sciences. I firmly believe that the furthering of scientific medicine requires a global effort. I have joined with my other three colleagues to edit a textbook, International Neurology, with the contributions from more than 200 neurologists from 80 countries around the world.

Reasons for Candidacy
As the WFN continues its endeavor to foster quality neurology and brain health worldwide, it serves as the bridge connecting different national neurology societies together. Its collective knowledge and strong moral standing lend the support to different national neurology societies to become a professional society with its own standing and as a pillar of democracy in their countries. I believe that I will be able to assist WFN to promote and sponsor initiatives that can leverage growth in neurology in regions of need, such as Africa, Central Asia, parts of Eastern Europe and Southeast Asia. Toward this goal, I believe that the WFN communications processes can be further improved to push for low-cost education in developing countries.

Goals
• To protect and grow the visibility of the WFN brand;
• To continue to modernize WFN communication and processes;
• To reach out and partner with other similarly aligned interests to assist the WFN in achieving its goals; and
• To assist in developing education programs worldwide.

Personal Qualities and Experience
The role of trustee requires a balance of experience, energy and teamwork. I believe I will contribute effectively to the stable growth of the WFN, the fulfillment of its mission and the achievement of the stated goals. Listed are some of the positions that I have held, or currently occupy, supporting my candidacy:
• Clinical professor, neurology, University of California, Riverside
• Chair, Education Committee, International Association for Parkinsonism and Related Disorders
• Member, Education Committee, WFN (2013-present)
• Member, Publication and Website Committee, WFN (2002-2012)
• Member, Fundraising Committee, WFN (2005-2009)
• Member, Membership Committee, WFN (2003-2007 and 2012-2013)

• Member, Research Committee on Parkinson’s Disease, WFN, (2004-2010)
• Member, Membership Committee, WFN (2009-2013)
• Member, Lawrence C. McHenry Award Subcommittee, American Academy of Neurology (2007-2011)
• Member, International Subcommittee, American Academy of Neurology (2013-2015)
• Member, Congress Fundraising Committee, International Association for Parkinsonism and Related Disorders (2013-2015)
• Member, Liaison/Public Relations Committee, Movement Disorder Society (2006-2010)
• Member, Strategic Planning Committee, Movement Disorder Society (2014-2015)
• Member, International Committee, American Academy of Neurology (1995-1997)
• Ad Hoc reviewer, American Academy of Neurology (2007-2008)
• Section editor, Journal of Neurological Sciences (2013-present)
• Section editor, Journal of Neural Transmission (2008-present)
• Editorial board, Journal of Neurological Sciences (2006-2013)
• Editorial board, Future Neurology (2007-present)
• Editorial board, World Neurology (2003-2013)
• Section editor, Neurology International (2009-present)
• Editorial board, Romania Journal of Neurology (2013-present)

The sources of finances for the WFN include membership dues and income from congresses and publications. Moving the World Congress of Neurology from a four-year to a two-year cycle has brought in more money. Going to a one-year cycle of meetings would allow not only for continuity in organization and strengthening of corporate identity, but also would further increase income, a welcome move in a time of shrinking resources. Engaging with partners to share costs should bring additional sources of revenue. As a long-standing member of the Executive Committee of the ENS, where I was in charge of the finances, I bring the needed managerial experience. I am convinced that I can fulfill this important function of treasurer to the satisfaction of the WFN and its members.
Pre-Announcement

57th Annual Meeting of the Japanese Society of Neurology

Toward Treatable Neurology

President
Ryuji Kaji
Professor, Department of Neurology,
Institute of Biomedical Sciences, Tokushima University Graduate School

Date
May 18 (wed) to 21 (sat), 2016

Venue
Kobe Convention Center
Kobe International Conference Center / Kobe International Exhibition Hall
Kobe Portopia Hotel

[Head Quarters Office] Department of Neurology, Institute of Biomedical Sciences, Tokushima University Graduate School
13-18-15 Kuramotocho, Tokushima-shi, Tokushima, 770-8503, Japan